Passa al contenuto
Merck

Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.

Nature communications (2019-09-15)
Patrick L Leslie, Yvonne L Chao, Yi-Hsuan Tsai, Subrata K Ghosh, Alessandro Porrello, Amanda E D Van Swearingen, Emily B Harrison, Brian C Cooley, Joel S Parker, Lisa A Carey, Chad V Pecot
ABSTRACT

Lymph node (LN) metastases correspond with a worse prognosis in nearly all cancers, yet the occurrence of cancer spreading from LNs remains controversial. Additionally, the mechanisms explaining how cancers survive and exit LNs are largely unknown. Here, we show that breast cancer patients frequently have LN metastases that closely resemble distant metastases. In addition, using a microsurgical model, we show how LN metastasis development and dissemination is regulated by the expression of a chromatin modifier, histone deacetylase 11 (HDAC11). Genetic and pharmacologic blockade of HDAC11 decreases LN tumor growth, yet substantially increases migration and distant metastasis formation. Collectively, we reveal a mechanism explaining how HDAC11 plasticity promotes breast cancer growth as well as dissemination from LNs and suggest caution with the use of HDAC inhibitors.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Fenil metansolfonile fluoruro, ≥98.5% (GC)
Sigma-Aldrich
Anti-vinculina monoclonale, clone hVIN-1, ascites fluid
Sigma-Aldrich
Leupeptina, microbial, ≥90% (HPLC)
Sigma-Aldrich
Inibitore della tripsina, lyophilized powder
Sigma-Aldrich
Benzamidine, ≥95.0%
Sigma-Aldrich
Anticorpo anti-acetil-istone H3, from rabbit
Sigma-Aldrich
Benzamidine hydrochloride hydrate, ≥99%
Sigma-Aldrich
Anticorpo anti-acetil-istone H4, 1 mg/mL, Upstate®
Sigma-Aldrich
Anti-Histone Deacetylase 11 (HDAC11) antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution